anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The Coronavirus disease 19 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a threat to human health. Although the COVID-19 pandemic is finished, some peoples are still suffering from this disease. Herein, we report the first case of SARS-CoV-2-associated Guillain-Barré syndrome (GBS) presenting as polyneuritis cranialis (PNC) and acute panautonomic neuropathy (APN) variants, accompanied by mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) and hyponatremia.
CASE PRESENTATION: A 32-year-old female patient with symptoms indicating multiple cranial nerve involvement, as well as sympathetic and parasympathetic nervous system dysfunction, was diagnosed as SARS-CoV-2-associated GBS presenting as PNC and APN variants, accompanied by MERS and hyponatremia. Following treatment with immunoglobulin, methylprednisolone, and symptomatic care, the patient's inflammatory cytokines and serum sodium became normal. However, some residual symptoms such as postural hypotension, fatigue, and mild dysarthria persisted at the 9-month follow-up.
CONCLUSION: This case highlights the unique presentation of SARS-CoV-2 infection. The involvement of both the central nervous system (CNS) and the peripheral nervous system (PNS) in this case underscores the complex neurological manifestations of COVID-19. Although the exact underlying pathogenesis of this case is unclear, inflammatory cytokines, particularly IL-6, may be implicated. Further research is needed to better understand the mechanisms underlying these complications and to optimize treatment strategies for affected patients.
Cancer vaccines are emerging as important tools for cancer treatment and prevention. Unfortunately, the cohorts that ultimately will benefit most from the vaccines, those at elevated risk for cancer, are likely to be stressed. Chronic stress can impair immune function, including immune response to vaccines. An inadequate response to vaccines can weaken their protective effect. Women at elevated risk for breast cancer can experience significant levels of distress and have associated immune function decrements. Interventions to treat distress-related immune decrements among these women are needed because these women will be among the first candidates for breast cancer vaccines. In theory, stress-management interventions should improve immune function and response to vaccines; however, the findings to date are mixed. The proposed investigation will conduct an exploratory randomized clinical trial to collect preliminary data on the efficacy of a cognitive behavioral stress management (CBSM) group intervention among women who are at elevated risk for breast cancer because of family history and who are reporting elevated levels of distress. Study outcomes will include antibody and cellular immune response to hepatitis A vaccine and self-reported distress.
PURPOSE: A newly divided lactobacillus fermentum strain with virus infection inhibitory activity is provided to be effectively used for preventing and treating viral diseases of animals. CONSTITUTION: A newly divided lactobacillus fermentum strain has virus infection inhibitory activity. The composition for preventing and treating infectious diseases due to the animal virus except human includes the lactobacillus fermentum CJL-112 as the active ingredient. The virus is RNA virus or DNA virus. The virus is orthomyxovirus, paramyxovirus, coronavirus, arterivirus, herpesvirus, and adenovirus. The feed additive for livestock or drinking water includes the lactobacillus fermentum CJL-112 as the active ingredient. A treating or preventing method for the infectious diseases due to the virus of animal except human comprises the following step: dosing the lactobacillus fermentum CJL-112 or the composition including the same to the entity which needs the treatment.
Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
BACKGROUND: Successful use of carbapenems in combination with cefazolin or oxacillin for treatment of MSSA bacteraemia has been described; however, comparative data to standard treatment approaches are lacking.
METHODS: This was a multicentre, retrospective study of adult patients with MSSA bacteraemia for >48 h. Standard treatment was considered monotherapy with cefazolin, oxacillin or nafcillin. Combination therapy was defined as the addition of ertapenem or meropenem to standard treatment for at least 24 h. The primary outcome was duration of bacteraemia defined as time from administration of an antibiotic with in vitro activity to first negative blood culture. Time to blood culture sterilization was compared through risk-set matching with aid of a propensity score.
RESULTS: Overall, 238 patients were included; 66% (157/238) received standard treatment and 34% (81/238) received combination therapy. The median (IQR) time to carbapenem initiation was 4.7 (3.63-6.5) days. Patients who received combination therapy were younger (P = 0.012), more likely to have endocarditis (P = 0.034) and had longer median duration of bacteraemia (P < 0.001). After applying risk-set matching, patients who received combination therapy experienced faster time to blood culture sterilization compared with control patients [HR = 1.618 (95% CI; 1.119-2.339) P = 0.011]. Using a paired hazard model, 90 day mortality rates were not statistically different among patients who received combination therapy versus matched controls [HR = 1.267 (95% CI; 0.610-2.678), P = 0.608].
DISCUSSION: Carbapenem combination therapy resulted in faster time to blood culture sterilization, but no differences in overall mortality rates. Randomized trials are critical to determine the utility of carbapenem combination therapy.
The present invention is directed to methods for stimulating primary and secondary effector cell responses for cellular immunotherapy. Cellular immunotherapy can successfully prevent or treat various viral infections and tumors, such as posttransplant EBV lymphoma. The present invention offers a general method for effecting cellular immunotherapy by providing for presentation, by the most effective antigen presenting cells, viral particles or specific antigens, without the need to develop an active viral infection in the antigen presenting cells. Furthermore, the present invention provides for generating effector cells against more than one opportunistic pathogen, e.g., Epstein-Barr virus and adenovirus. The effector cells generated according to the invention, which include CD4 and CD8 cells, are extremely long lived in vivo after adoptive transfer. In specific embodiments, dendritic cells present whole adenovirus particles via class I MHC molecules, transduced dendritic cells present a weak EBV antigen to effector cells, and EBV-transformed lymphoblastoid cells present whole adenoviral particles to effector cells, generating a population of effector cells active against EBV and adenovirus. Moreover, the adenovirus-specific effector cells of the present invention, generated against one adenovirus subgroup, recognize different adenovirus subgroups.
PROBLEM TO BE SOLVED: To obtain a smooth muscle relaxant having excellent relaxant action for smooth muscles and also expressing excellent relaxant action on matrical smooth muscle and vascular smooth muscle. SOLUTION: This smooth muscle relaxant contains one or more of ligustilide dimer selected from the compounds expressed by formulas I, II and III, their enantiamers and their racemic bodies as effective ingredients. The compound of formula III is new and is obtained by extracting angelicae radix from China with hexane, fractionating, purifying and crystallizing the extract. The compound can be formulated in tablets, granules, fine granules, powders, injections, etc., by usual methods. The dose is 0.1-500mg dimer of ligustilide/adult/day and is administered in 1-3 times a day. The relaxant can be used for preventing and curing urgent premature birth, dysmenorrhea, hypertension, etc.
Risk Summary   
There are no adequate and well-controlled studies of SPY AGENT GREEN in pregnant women. Available data from a very small number of scientific literature studies with indocyanine green use in pregnant women over several decades have not reported any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Data from one small study in which indocyanine green was administered intravenously to pregnant women during labor suggest there is no placental transfer of the drug. Animal reproduction studies have not been conducted with indocyanine green. 

All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Rationale: The American Thoracic Society recommended a single reference equation for spirometry, but the impact on patients is not known. Objectives: To estimate the effect of changing to a single reference equation among veterans with chronic obstructive pulmonary disease (COPD). Methods: A cross-sectional study was conducted including veterans aged ⩾40 to ⩽89 years with COPD and spirometry results from 21 facilities between 2010 and 2019. We collected race and ethnicity data from the electronic health record. We estimated the percentage change in the number of veterans with lung function meeting clinical thresholds used to determine eligibility for lung resection for cancer, lung volume reduction surgery (LVRS), and lung transplantation referral. We estimated the change for each level of U.S. Department of Veterans Affairs service connection and financial impact. Results: We identified 44,892 veterans (Asian, 0.5%; Black, 11.8%; White, 80.8%; and Hispanic, 1.8%). When changing to a single reference equation, Asian and Black veterans had reduced predicted lung function that could result in less surgical lung resection (4.4% and 11.1%, respectively) while increasing LVRS (1.7% and 3.8%) and lung transplantation evaluation for Black veterans (1.2%). White veterans had increased predicted lung function and could experience increased lung resection (8.1%), with less LVRS (3.3%) and lung transplantation evaluation (0.9%). Some Asian and Black veterans could experience increases in monthly disability payments (+$540.38 and +$398.38), whereas White veterans could see a decrease (-$588.79). When aggregated, Hispanic veterans experienced changes attributable to their racial identity and, because this sample was predominantly Hispanic White, had similar results to White veterans. Conclusions: Changing the reference equation could affect access to treatment and disability benefits, depending on race. If adopted, the use of discrete clinical thresholds needs to be reassessed, considering patient-centered outcomes.
RIRS will be performed with SP TFL or Ho:YAG (100 W). The procedure is performed under general anesthesia with the patient in the dorsal lithotomy position. The bladder is entered either with a cystoscope or a semi-rigid ureterorenoscope. Guidewires (0.035") will be used to facilitate access (under fluoroscopic guidance). After access sheath (12/14) will be placed up to the kidney pelvis. Through the access sheath ureteroscope will be introduced. For nephrolithotripsy 145 mcm and 200 mcm fibers will be used. Large fragments could be extracted with nitinol basket. After the surgery ureteral stent (7 Fr.) will be placed inside the ureter for 10 to 14 days.

A 10 Fr urethral catheter can be placed in the bladder for the drainage of the bladder during the operation.
The utility model discloses a bamboo charcoal pomander. The outer box of the pomander presents a cube shape or a cylindrical shape, and is made of paper, plastic or wood. The inside of the bamboo charcoal pomander is provided with aromatic material. The outer box of the pomander is divided to three layers. The aromatic material includes bamboo charcoal particles filled in the upper layer and the lower layer, and essential oil in the middle layer. The upper part of the box body of the outer box is provided with a set of small holes which are used for ventilation and slow aroma release. The upper part of the box body of the outer box is provided with an adhesive layer, and can be fixed to a bedplate in the front of a motor vehicle, a desk in a living room, an office table in an office, and other table surfaces which can be used for fixation. The utility model utilizes the absorbing ability of bamboo charcoal to store aroma in holes, which realizes the slow release of aroma and prolongs the release time of aroma. In addition, the bamboo charcoal also has the functions of absorbing harmful gases of benzene, formaldehyde, TVOC and the like, and releasing far infrared ray and negative ions. The utility model has the functions of purifying air, relieving pressure, conditioning skin, appeasing anxiety and depression and the like.
A total of 150 subjects in this group received rizvilutamide daily for 6 cycles along with ADT. Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
This proposal will evaluate the effects of Bosutinib (Bosulif, Pfizer®) treatment - an FDA-approved tyrosine kinase inhibitor that targets c-Abelson (Abl) and Src tyrosine kinases- in patients with DLB. Investigators have demonstrated safety and efficacy of this compound in pre-clinical animal models and others have shown similar benefits of Bosutinib on inflammation and neurotoxic protein clearance in neurodegeneration. Investigators have demonstrated that Bosutinib enters the brain (5% CSF:plasma ratio) and inhibits Abl at lower doses (5mg/kg) than the cancer dose (80mg/kg) in animals. Bosutinib also reduces the levels of neurotoxic proteins including alpha-synuclein, tau and beta-amyloid and improves motor and cognitive behavior in models of neurodegeneration. The use of Bosutinib is a novel strategy that promotes autophagy to clear neurotoxic protein aggregates in neurons. Bosutinib is FDA-approved for the treatment of chronic myelogenous leukemia (CML) at an oral dose of 400-600 mg daily. Based on our preclinical evidence, investigators used allometric conversion to extrapolate animal to human dose and estimated a human equivalent dose daily dose of 100mg Bosutinib in this clinical study to determine the safety and tolerability, pharmacokinetics and pharmacodynamics in patients with mild to moderate DLB.
The application relates to a polypeptide and application thereof, in particular to a polypeptide for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis and application thereof. The amino acid sequence of the polypeptide for promoting the proliferation of the liver cells and/or inhibiting the apoptosis of the liver cells is at least one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The polypeptide has the activity of promoting the proliferation of liver cells and/or inhibiting the apoptosis of liver cells, which is equivalent to or better than HIP/PAP, and has the advantages of small molecular weight, easy synthesis, low immunogenicity and the like, so that the polypeptide has wide application prospect.
High endotracheal cuff pressure (ETCP) during surgical retractor splay associates with recurrent laryngeal nerve paresis/ palsy and results in post-anterior cervical spine surgery (post-ACSS) dysphonia. Control of intraoperative ETCP during ACSS may benefit voice outcome. The taper-shaped tracheal tube cuff was originally designed as a new strategy to reduce fluid leakage across the conventional cylindrical cuff and prevention of ventilator associated pneumonia. Literature has revealed the just seal pressure for the tapered-shaped tracheal tube (TT) cuff was lower than conventional cylindrical cuff. Therefore the investigators hypothesize that use of a tapered-shaped ET cuff during the surgery can lead to a lower ETCP during retractors splay and improve voice recovery after ACSS. In this study, 80 patients were randomized into 2 groups, to receive endotracheal intubation using TaperGuard tracheal tube (tapered- shaped cuff) or a conventional tracheal tube (a cylindrical cuff). The just seal pressure, intraoperative cuff pressure, and postoperative sore throat and voice outcome are recorded and compared.
The composition is new. The composition comprises, in physiologically acceptable medium, a dispersion of particles of first film-forming polymeric system, containing first polymer surface-stabilized in fatty liquid phase, and also a dispersion of particles of second non- film-forming polymeric system, surface-stabilized in fatty liquid phase. First polymeric system has glass transition temperature up to 40 degrees C (preferably (-100) to 40 degrees C, especially (-10) to 30 degrees C), and second polymeric system has glass transition temperature above 40 degrees C (preferably 40-300 degrees C, especially 45-150 degrees C. First and/or second polymeric system comprises at least one plasticizer and the particles of each system are stabilized by stabilizer selected from sequence, grafted and statistic polymers and their mixtures. The total of first and second polymers dispersed in fatty liquid phase amounts to 2-60 wt.% (preferably 5-30 wt.%) per total wt. of composition, and the wt. ratio of first polymer to second is 1/99-99/1, preferably 50/50 to 80/20. The composition is preferably anhydrous and may additionally contain at least one wax, and/or at least one liposoluble polymer, and/or at least one additive selected from thickeners of fatty liquid phase, perfume, preservatives, surfactants, sequestrants, vitamins, proteins, ceramides, alkalinizing or acidifying agents, emulsifiers, colorants and fillers. Independent claims are also included for : (1) process of make-up or non-therapeutic treatment of keratinic matters comprising application of composition as claimed; and (2) the use of composition as claimed to produce brilliant and/or non-sticky and/or wear-resistant and/or non-transferable film on keratinic matter, especially on keratinic fibres; or for curling keratinic fibres, namely eyelashes.
Participants in both groups (Dep/SI and Dep/SB) will undergo identical assessments at baseline, 6 months, and 12 months. Assessments will include clinical interviews and rating scales, questionnaires (including a self-report scale of negative urgency), and single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) measurement of cortical inhibition.
The study will be prospective non-interventional and will include patients with kidney stones who are to undergo one of the following three techniques: retrograde nephrolithotripsy, percutaneous nephrolithotripsy and extracorporeal nephrolithotripsy depending on the size of the stone. The study will take place at the 2nd Urology Clinic of the University of Athens, at the Sismanoglio Hospital of Athens. It will include patients diagnosed with kidney stones after plain X-ray and/or CT scan. Percutaneous nephrolithotripsy will be performed on stones \> 2 cm, while extracorporeal or retrograde nephrolithotripsy on stones \< 2 cm. Patient demographics (age, gender, body mass index, comorbidities, anticoagulant use), stone-related data (maximum stone size, anatomic location of stone, number of stones, presence of hydronephrosis preoperatively, presence of piglet catheter preoperatively, positive urine culture, preoperative chemoprophylaxis ) as well as information about the operation (type of anesthesia, operation time, hospitalization time) will be reported. Finally, all possible complications will be recorded intraoperatively, immediately postoperatively and up to 30 days after the day of surgery. This will be followed by a statistical analysis of the resulting data and a comparison between the CDC and CCI systems using the SPSS statistical program. To describe continuous variables, the mean/standard deviation will be used if it is a normal distribution, or the median and range if it is a non-normal distribution. The Shapiro-Wilk test will be used to investigate the distribution of the data. The absolute number and the corresponding percentage will be used to describe the qualitative variables. For the comparison of continuous variables, the parametric t-test will be used if the data follow a normal distribution, or the Mann-Whitney U test if they do not follow a normal distribution. Chi-square and Fisher's exact test will be used to compare qualitative variables. Exclusion criteria from this study are:

1. Non-acceptance by the patient of his participation or inability to understand the purposes and procedures of the study.
2. Recent similar operation that the patient has undergone (interval of less than one month).
BACKGROUND: The increasing admissions of very elderly patients to intensive care units (ICUs) over recent decades highlight a growing need for understanding acute kidney injury (AKI) in this population. Although these individuals are potentially at high risk for AKI and adverse outcomes, data on AKI in this population is scarce. This study investigates the AKI incidence and outcomes of critically-ill patients aging at least 90 years.
METHODS: This retrospective cohort study conducted at the Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Germany (2008-2020), investigates AKI incidence and outcomes between 2008 and 2020 in critically-ill patients aged ≥ 90 years. AKI was defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria using creatinine dynamics and/or urine output. Primary endpoint was overall mortality after 1 year. Secondary endpoints were in-hospital mortality, length of ICU and hospital stay.
RESULTS: During the study period 92,958 critically-ill patients were treated and 1108 were ≥ 90 years. Of these, 1054 patients had available creatinine values and were included in the present study. AKI occurred in 24.4%, mostly classified as mild (17.5%). AKI was independently associated with a significant increase in overall mortality (HR 1.21, 95 %-CI: 1.01-1.46), in-hospital mortality (OR 2, 1.41-2.85), length of ICU (+2.8 days, 2.3-3.3) and hospital stay (+2.3 days, 0.9-3.7). Severity escalated these effects, but even mild AKI showed significance. Introducing urine-based criteria increased incidence but compromised mortality prediction.
CONCLUSIONS: AKI is a frequent complication in very elderly critically-ill patients. Occurrence of AKI at any stage was associated with increased mortality. Predictive ability applied to AKI defined by creatinine but not urine output. Careful attention of creatinine dynamics is essential in very elderly ICU-patients.
PURPOSE:To provide the titled composition having high safety and effective to prevent the falling-off of hair, dandruff and itchiness, and to promote the sprouting and growth of hair, by using gibberellin which is a substance prmoting the growth of higher vegetables and produced by the fungus causing Bakanae disease in rice, as an active component. CONSTITUTION:Gibberellin which is used mainly as a plant growth regulating agent for the improvement in the yield and quality of crops, e.g. production of seedless grape, promotion of the growth of grape, cucumber, etc., is used as an active component of hair tonic. The amount of the active component in the hair tonic composition is 0.001-5wt%, preferably 0.05-1.0wt%. The hair tonic composition may contain various components for hair tonic as well as gibberellin, e.g. solvent such as pure water, ethanol, etc., refreshing agent such as menthol, wetting agent such as propylene glycol, emollient such as lactic acid, etc.